{"id":"W4308349064","doi":"10.1016/s2213-2600(22)00434-9","title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","year":2022,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hospital for Sick Children","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Chiesi USA; National Institutes of Health; Nabriva Therapeutics; Vertex Pharmaceuticals; Insmed; Gilead Sciences; Cystic Fibrosis Foundation; Genentech; AstraZeneca; GlaxoSmithKline; National Heart, Lung, and Blood Institute; American Thoracic Society","keywords":"Medicine; Hypertonic saline; Cystic fibrosis; Discontinuation; Randomized controlled trial; Ivacaftor; Clinical trial; Internal medicine; Physical therapy; Cystic fibrosis transmembrane conductance regulator","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008816918,0.0004622531,0.003629722,0.0002542341,0.0002681925,0.00004860374,0.0006990778,0.00008455629,0.001272583],"category_scores_gemma":[0.029003,0.0002465451,0.0001196573,0.001101872,0.000350365,0.0002664133,0.0002884255,0.0006515539,0.000009271028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005997778,"about_ca_system_score_gemma":0.0008908283,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005589148,"about_ca_topic_score_gemma":0.007273132,"domain_scores_codex":[0.9922307,0.002439707,0.002228388,0.0007599747,0.001677754,0.0006635065],"domain_scores_gemma":[0.982085,0.01434373,0.001477779,0.001303861,0.0005172744,0.0002723332],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9420234,0.0006585936,0.002308828,0.00007603861,0.0005209499,0.0001021834,0.001226156,0.001506045,0.04130905,0.00002780887,0.005433136,0.004807818],"study_design_scores_gemma":[0.9383941,0.007779455,0.02394208,0.0008428372,0.001036512,0.00001063192,0.001393146,0.01774544,0.001044885,0.00004320061,0.007420022,0.0003476334],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800402,0.002542868,0.0003177341,0.004012733,0.0003239455,0.010468,0.001661024,0.00007302239,0.0005604646],"genre_scores_gemma":[0.9934793,0.0002078499,0.001637149,0.0004327223,0.0009433384,0.001709078,0.001202199,0.00006403487,0.0003243944],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04026417,"threshold_uncertainty_score":0.9999987,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1101472016697327,"score_gpt":0.3964294450731055,"score_spread":0.2862822434033727,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}